Recursion reports 2025 financial results and outlines 2026 milestones
Recursion reported 2025 results with $74.7 million in revenue, a $644.8 million net loss, and $753.9 million in cash supporting operations into early 2028. The company announced clinical validation of its AI drug‑discovery platform in familial adenomatous polyposis, more than $500 million earned from partner milestones, continued collaborations with Sanofi, Roche and Genentech, and multiple Phase 1 readouts and regulatory engagements expected in 2026.
Why it mattersClinical validation in familial adenomatous polyposis and Phase 1 readouts justify reassessing partnerships and financing given $753.9M runway.
Entities Mentioned
Recursion PharmaceuticalsSanofiRocheGenentech